Drug interactions
Sarilumab + Tisagenlecleucel
Severity: Major
Sarilumab and Tisagenlecleucel: major interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Sarilumab blocks interleukin-6 signalling and is used to manage cytokine release syndrome and inflammatory disease, so it may blunt CAR-T cell activity or expansion. Both agents impair immune defences, which adds to the infection risk in patients who are often already lymphodepleted and neutropenic.
What this interaction means in plain words
Sarilumab and Tisagenlecleucel can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.
Sarilumab belongs to Musculoskeletal; Tisagenlecleucel belongs to Oncology.
Why it happens
Additive immunosuppression through IL-6 receptor blockade, which may also attenuate CAR-T cell expansion and function.
What to do
Avoid giving sarilumab around the time of CAR-T infusion unless it is needed to treat cytokine release syndrome under specialist direction. Monitor closely for infection and for loss of CAR-T response.
What to ask your pharmacist
- Does the benefit of taking both outweigh the risk in my case?
- Do I need any blood test, ECG or other check while on both?
- What early warning signs should I watch for, and what should I do if they appear?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Sarilumab and Tisagenlecleucel, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Sarilumab
Other interactions of Tisagenlecleucel
Frequently asked questions
Can I take Sarilumab with Tisagenlecleucel?
MediHelp rates the interaction as major. Sarilumab and Tisagenlecleucel can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Sarilumab blocks interleukin-6 signalling and is used to manage cytokine release syndrome and inflammatory disease, so it may blunt CAR-T cell activity or expansion. Both agents impair immune defences, which adds to the infection risk in patients who are often already lymphodepleted and neutropenic.
How serious is the interaction between Sarilumab and Tisagenlecleucel?
MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid giving sarilumab around the time of CAR-T infusion unless it is needed to treat cytokine release syndrome under specialist direction. Monitor closely for infection and for loss of CAR-T response.
What other medicines interact with Sarilumab?
MediHelp also lists interactions of Sarilumab with, for example, Adenovirus types 4 and 7 live, Bcg vaccine live, Dengue vaccine. The full list is on the Sarilumab page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
